4//SEC Filing
Fridriksdottir Hafrun 4
Accession 0001209191-22-014469
CIK 0000818686other
Filed
Mar 1, 7:00 PM ET
Accepted
Mar 2, 7:47 AM ET
Size
10.1 KB
Accession
0001209191-22-014469
Insider Transaction Report
Form 4
Fridriksdottir Hafrun
Executive VP, Global R&D
Transactions
- Exercise/Conversion
Restricted Share Units
2022-02-28−21,682→ 43,366 total→ Ordinary Shares (21,682 underlying) - Exercise/Conversion
Ordinary Shares
2022-02-28+21,682→ 73,098.514 total - Sale
Ordinary Shares
2022-02-28$8.14/sh−7,590$61,799→ 65,508.514 total
Footnotes (6)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.035 to $8.255, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Restricted share units were granted on February 28, 2020, with 21,682 having vested on each of February 28, 2021 and February 28, 2022, 21,682 vesting on February 28, 2023 and 21,684 vesting on February 28, 2024.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001561458
Filing Metadata
- Form type
- 4
- Filed
- Mar 1, 7:00 PM ET
- Accepted
- Mar 2, 7:47 AM ET
- Size
- 10.1 KB